false
0000946644
0000946644
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 17, 2026
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-27072 |
|
52-0845822 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 2117
SW Highway 484, Ocala, Florida |
|
34473 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
symbol |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
AIM |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
7.01 |
Regulation
FD Disclosure. |
On
November 18, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing that it had adjourned its 2026 Annual
Meeting of Stockholders. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
On
November 17, 2026, the Company convened and then determined to adjourn, without conducting any business, its 2026 Annual Meeting of Stockholders
(the “Annual Meeting”) because the Company did not have a sufficient number of shares of the Company’s common stock
present or represented by proxy at the Annual Meeting to constitute a quorum and to provide stockholders additional time to review the
proxy materials and submit proxies to vote at the Annual Meeting. As was announced at the Annual Meeting, such meeting will reconvene
at 11:00 A.M. Eastern Time on December 8, 2026, virtually at https://web.viewproxy.com/AIM/2026.
The
record date for the determination of stockholders of the Company entitled to vote at the adjourned Annual Meeting remains the close of
business on September 28, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting.
Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any
action.
| Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release, dated November 18, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
November 18, 2026 |
AIM
ImmunoTech Inc. |
| |
|
|
| |
By: |
/s/
Thomas K. Equels |
| |
|
Thomas
K. Equels |
| |
|
Chief
Executive Officer |
Exhibit
99.1

AIM
ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
OCALA, Fla., November 18, 2026 / AIM
ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that its 2026
Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for and convened on November 17, 2026, has been
adjourned until December 8, 2026 at 11:00 A.M. Eastern Time, because the Company did not have a sufficient number of shares of the Company’s
common stock present or represented by proxy at the Annual Meeting to constitute a quorum and to provide stockholders additional time
to review the proxy materials and vote on the proposals described in the Company’s definitive proxy statement for the Annual Meeting
filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2026 (the “Annual Meeting Proxy
Statement”).
A quorum would have been present if shares representing 33 and 1/3% of the common stock outstanding and entitled
to vote were present at the Annual Meeting or represented by proxy. At the time the Annual Meeting was adjourned, proxies had been submitted
by stockholders representing approximately 32.5% of the outstanding shares of stock entitled to vote, so a quorum did not exist.
The
Annual Meeting will be reconvened on December 8, 2026 at 11:00 A.M. Eastern Time and will continue to be held in a virtual format. Stockholders
will be able to virtually attend the Annual Meeting by visiting https://web.viewproxy.com/AIM/2026.
The
record date for the determination of stockholders of the Company entitled to vote at the adjourned Annual Meeting remains the close of
business on September 28, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting.
Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any
action.
About
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma
company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic
cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown
broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com
and connect with the Company on X, LinkedIn, and Facebook.
Cautionary
Statement
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements set forth in this press release speak only as
of the date hereof. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could
cause actual results to differ materially. Such forward-looking statements may include statements relating to the timing of the Annual
Meeting and related matters. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The Company does not undertake to update any forward-looking statements except as required
by applicable law.
For
a discussion of risk factors, please see the Company’s filings with the U.S. Securities and Exchange Commission, including its
most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, available at www.sec.gov and www.aimimmuno.com.
You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other
websites referenced or linked to in this press release is not incorporated by reference into this press release and such information
is referenced or linked for reference purposes only.
Investor
Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com